A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene

Journal of Biological Chemistry

Volumn 288, Issue 17, 2013, Pages 12305-12312

  Wei, Hui ^a   Bera, Tapan K ^a   Wayne, Alan S ^a   Xiang, Laiman ^a   Colantonio, Simona ^b   Chertov, Oleg ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADP-RIBOSYLATION; IMMUNOTOXINS; LYMPHOMA CELLS; METHYL GROUP; MUTANT CELLS; RESISTANT CELLS;

ALKYLATION; CELL CULTURE; CELLS; DISEASES; FUNCTIONAL GROUPS; PATIENT TREATMENT;

GENE THERAPY;

DIPHTHAMIDE; ELONGATION FACTOR 2; HISTIDINE; IMMUNOTOXIN; IMMUNOTOXIN HA22; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG RESISTANCE; DRUG SENSITIVITY; GENE; GENE DELETION; GENE INACTIVATION; GENE SILENCING; LYMPHOMA CELL; LYMPHOMA CELL LINE; MUTANT; PRIORITY JOURNAL; WDR85 GENE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE DELETION; HISTIDINE; HUMANS; IMMUNOTOXINS; LYMPHOMA; METHYLATION; METHYLTRANSFERASES; NEOPLASM PROTEINS; PEPTIDE ELONGATION FACTOR 2; PROTEINS;

PSEUDOMONAS EXOTOXIN;

EID: 84876938118     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.461343     Document Type: Article

References (34)

1. Howlader, N., Noone, A. M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S. F., Kosary, C. L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M. P., Lewis, D. R., Chen, H. S., Feuer, E. J., and Cronin, K. A. (eds) (2009) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute, Bethesda, MD, http://seer.cancer. gov/csr/1975-2009-pops09/
2. Ries, L. A. G., Percy, C. L., and Bunin, G. R. (1999) Introduction. in Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995 (Reis, L. A. G., Smith, M. A., Gurney, J. G., Linet, M., Tamra, T., Young, J. L., and Bunin, G. R., eds) NIH Publication No. 99-4649, pp. 1-16, National Cancer Institute, SEER Program, Bethesda, MD, http://seer.cancer.gov/publications/childhood/
3. Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., Schwartz, C. L., Leisenring, W., and Robison, L. L., and Childhood Cancer Survivor Study (2006) Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572-1582
4. Wayne, A. S., Reaman, G. H., and Helman, L. J. (2008) Progress in the curative treatment of childhood hematologic malignancies. J. Natl. Cancer Inst. 100, 1271-1273
5. Wayne, A. S., Kreitman, R. J., Findley, H. W., Lew, G., Delbrook, C., Steinberg, S. M., Stetler-Stevenson, M., FitzGerald, D. J., and Pastan, I. (2010) Anti-CD22 immunotoxin RFB4 (dsFv)-PE38 (BL22) for CD22 positive hematologic malignancies of childhood: pre-clinical studies and phase I clinical trial. Clin. Cancer Res. 16, 1894-1903
6. Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M., Fitzgerald, D. J., Lechleider, R., and Pastan, I. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 30, 1822-1888
7. Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J., and Pastan, I. (2002) Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res. 8, 995-1002
8. FitzGerald, D. J., Wayne, A. S., Kreitman, R. J., and Pastan, I. (2011) Treatment of hematologic malignancies with immunotoxins and antibodydrug conjugates. Cancer Res. 71, 6300-6309
9. Greganova, E., Altmann, M., and Bütikofer, P. (2011) Unique modifications of translation elongation factors. FEBS J. 278, 2613-2624
10. Carette, J. E., Guimaraes, C. P., Varadarajan, M., Park, A. S., Wuethrich, I., Godarova, A., Kotecki, M., Cochran, B. H., Spooner, E., Ploegh, H. L., Brummelkamp, T. R. (2009) Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231-1235
11. Su, X., Chen, W., Lee, W., Jiang, H., Zhang, S., and Lin, H. (2012) YBR246W is required for the third step of diphthamide biosynthesis. J. Am. Chem. Soc. 134, 773-776
12. Wayne, A. S., Bhojwani, D., Silverman, L. B., Richards, K., Stetler-Stevenson, M., Shah, N., Jeha, S., Pui, C.-H., Buzoianu, M., Fitzgerald, D. J., Kreitman, R. J., Ibrahim, R., and Pastan, I. (2011) A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia. Blood 118, Abstr. 248, 1317
13. Wei, H., Xiang, L., Wayne, A. S., Chertov, O., FitzGerald, D. J., Bera, T. K., and Pastan, I. (2012) Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc. Natl. Acad. Sci. U. S. A. 109, 6898-6903
14. Pastan, I., Beers, R., and Bera, T. K. (2004) Recombinant immunotoxins in the treatment of cancer. Methods Mol. Biol. 248, 503-518
15. Du, X., Beers, R., Fitzgerald, D. J., and Pastan, I. (2008) Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 68, 6300-6305
16. Zhang, Y., Hansen, J. K., Xiang, L., Kawa, S., Onda, M., Ho, M., Hassan, R., and Pastan, I. (2010) A flow cytometry method to quantitate internalized immunotoxins shows that Taxol synergistically increases cellular immunotoxins uptake. Cancer Res. 70, 1082-1089
17. Chaudhary, V. K., Queen, C., Junghans, R. P., Waldmann, T. A., FitzGerald, D. J., and Pastan, I. (1989) A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339, 394-397
18. Fei, Z., Bera, T. K., Liu, X., Xiang, L., and Pastan, I. (2011) Ankrd26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. J. Biol. Chem. 286, 27761-27768
19. Du, X., Youle, R. J., FitzGerald, D. J., and Pastan, I. (2010) Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol. Cell. Biol. 30, 3444-3452
20. Zhang, Y., Zhu, X., Torelli, A. T., Lee, M., Dzikovski, B., Koralewski, R. M., Wang, E., Freed, J., Krebs, C., Ealick, S. E., and Lin, H. (2010) Diphthamide biosynthesis requires an organic radical generated by an iron-sulphur enzyme. Nature 465, 891-896
21. Mattheakis, L. C., Shen, W. H., and Collier, R. J. (1992) DPH5, a methyltransferase gene required for diphthamide biosynthesis in Saccharomyces cerevisiae. Mol. Cell. Biol. 12, 4026-4037
22. Baylin, S. B. (2011) Resistance, epigenetics and the cancer ecosystem. Nat. Med. 17, 288-289
23. Ogawa, H., Ishiguro, K., Gaubatz, S., Livingston, D. M., and Nakatani, Y. (2002) A complex with chromatin modifiers that occupies E2F-and Mycresponsive genes in G0 cells. Science 296, 1132-1136
24. Magrath, I. T., Freeman, C. B., Pizzo P., Gadek, J., Jaffe, E., Santaella, M., Hammer, C., Frank, M., Reaman, G., and Novikovs, L. (1980) Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface markers. J. Natl. Cancer Inst. 64, 477-483
25. Li, D., and Roberts, R. (2001) WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell. Mol. Life Sci. 58, 2085-2097
26. Nowak, N. J., Sait, S. N., Zeidan, A., Deeb, G., Gaile, D., Liu, S., Ford, L., Wallace, P. K., Wang, E. S., and Wetzler, M. (2010) Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 199, 15-20
27. Jensen, M. R., and Helin, K. (2004) OVCA1: emerging as a bona fide tumor suppressor. Genes Dev. 18, 245-248
28. Phillips, N., Ziegler, M., Saha, B., and Xynos, F. (1993) Allelic loss on chromosome 17 in human ovarian cancer. Int. J. Cancer 54, 85-91
29. Phillips, N. J., Zeigler, M. R., and Deaven, L. L. (1996) A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. Cancer Lett. 102, 85-90
30. Bruening, W., Prowse, A. H., Schultz, D. C, Holgado-Madruga, M., Wong, A., and Godwin, A. K. (1999) Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res. 59, 4973-4983
31. Chen, C. M., and Behringer, R. R. (2004) Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis. Genes Dev. 18, 320-332
32. Stewart, D. R., and Kleefstra, T. (2007) The chromosome 9q subtelomere deletion syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 145 C, 383-392
33. Bächner, D., Kreienkamp, H. J., and Richter, D. (2002) MIZIP, a highly conserved, vertebrate specific melanin-concentrating hormone receptor 1 interacting zinc-finger protein. FEBSLett. 526, 124-128
34. Francke, F., Buck, F., and Bächner, D. (2005) MYND domain specific interaction of the melanin-concentrating hormone receptor 1 interacting zinc-finger protein with α-and β-tubulin. Biochem. Biophys. Res. Commun. 334, 1292-1298